| Archbold Family Dental-brian A Custer Dmd Llc | |
|
311 W Holland St Archbold OH 43502-1125 | |
| (419) 445-8176 | |
| (419) 445-8177 |
| Full Name | Archbold Family Dental-brian A Custer Dmd Llc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 311 W Holland St, Archbold, Ohio |
| Authorized Official Name and Position | Brian Allan Custer (OWNER/DENTIST) |
| Authorized Official Contact | 4194458176 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Archbold Family Dental-brian A Custer Dmd Llc 311 W Holland St Archbold OH 43502-1125 Ph: (419) 445-8176 | Archbold Family Dental-brian A Custer Dmd Llc 311 W Holland St Archbold OH 43502-1125 Ph: (419) 445-8176 |
| NPI Number | 1225548746 |
|---|---|
| Provider Enumeration Date | 10/10/2017 |
| Last Update Date | 10/10/2017 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225548746 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | (Ohio) | Primary |
News Archive
Lung cancer is one of the most prevalent types of cancer, with more than 20,000 new cases diagnosed each year in Spain. Lung adenocarcinomas carrying oncogenic KRAS, the engine driving these tumours in 30% of cases, constitute the most aggressive sub-type because, unlike other types of lung cancer, there are no targeted therapies beyond the standard cisplatin-based treatment.
GOP challenger Mitt Romney said he would pay for military spending increases by repealing the 2010 health law and scaling back other health programs.
A European team of scientists have built the first atlas of white-matter microstructure in the human brain. The project's final results have the potential to change the face of neuroscience and medicine over the coming decade.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.
› Verified 5 days ago